Beigene has started using its flagship biopharmaceutical production base and clinical research center in the USA to continue driving global business expansion and bringing innovative drugs to more patients worldwide.
The new flagship facility located in New Jersey, USA, with a total investment of 0.8 billion US dollars, has advanced production capacity and clinical development capabilities for new anti-cancer drugs, which will support the company's global business growth and expansion. Hopewell, New Jersey, USA, July 23, 2024 / PRNewswire / - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) is a global innovative oncology company. Today, it announced the official opening of its new flagship base in Princeton West Innovation Park, Hopewell, New Jersey, USA. The base has been built with world-class technology.
Express News | BeiGene Opens U.S. Biologics Manufacturing And Clinical R&D Facility In New Jersey With $800M Investment
Express News | Beigene: Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
Executive Reshuffles: Otis Worldwide, HSBC and Rockwell Automation in Focus
BeiGene Appoints CFO
BeiGene Names Rosenberg Finance Chief as Wang Departs
Beigene (06160.HK) has appointed Aaron Rosenberg as its Chief Financial Officer.
Beigene (06160.HK) announced on July 18 that Aaron Rosenberg has been appointed Chief Financial Officer of the company, effective from July 22, 2024. Mr. Rosenberg will succeed Julia Wang, who will leave to seek external opportunities. Ms. Wang will continue to serve until the end of August to help with the transition.
BeiGene Announces New CFO Appointment and Senior Advisor Transition
Express News | Beigene - Aaron Rosenberg Has Been Appointed as Chief Financial Officer
Express News | Beigene Has Appointed Aaron Rosenberg As Chief Financial Officer, Effective July 22 Succeeding Julia Wang, Who Is Departing To Pursue External Opportunities And Will Stay With The Company Through August To Support The Transition
Express News | Beigene - Rosenberg Will Succeed Julia Wang
Express News | Beigene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
BeiGene: Julia Wang Is Departing to Pursue External Opportunities >BGNE
BeiGene Announces Appointment Of Aaron Rosenberg As Chief Financial Officer >BGNE
Nomura Adjusts BeiGene's Price Target to HK$158.37 From HK$150, Keeps at Buy
Nomura: Maintains Buy Rating for Beigene, Target Price Increased to HKD 158.37.
Nomura released a research report stating that it maintains a "buy" rating for Beigene (06160), with a target price raised from HKD 150 to HKD 158.37. The company is expected to achieve sales of $ 0.833 billion in the second quarter of the 2024 fiscal year, a 40% increase YoY and an 11% increase QoQ, which is 4% higher than market expectations. The bank stated that it has raised its revenue forecast for the company for fiscal years 2024 and 2025 by 14% each to $ 3.1 billion and $ 4 billion respectively. This is mainly due to the upward revision of the two-year sales forecast for Zanubrutinib, from the original $ 1.6 billion and $ 2 billion each to $ 2 billion and $ 2.5 billion each.
Nomura: Maintains a "buy" rating for Beigene (06160) with a target price of HKD 158.37.
Zhixin Finance App learned that Nomura released a research report stating that it maintains a "buy" rating on Beigene (06160) and raised its target price from HKD 150 to HKD 158.37. It is expected that the company's sales in the second quarter of fiscal year 2024 will reach USD 0.833 billion, a year-on-year increase of 40%, and a quarterly increase of 11%, which is 4% higher than the market expectation. The bank stated that it raised its revenue forecast for the company's fiscal year 2024 and 2025 by 14% each to USD 3.1 billion and USD 4 billion, mainly due to the increase in sales forecast of Zanubrutinib for two years, raised from the original USD 1.6 billion and USD 2 billion to USD 2 billion each.
Express News | BeiGene Shares Are Trading Lower After B of A Securities Maintained a Neutral Rating on the Stock and Lowered Its Price Target From $180 to $152.5
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading